FXN — Frataxin

📖 Wiki Page

gene1588 wordssynced 2026-04-02

FXN — Frataxin

...

FXN — Frataxin

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FXN — Frataxin</th>
</tr>
<tr> [@regulation2024]
<td class="label">Symbol</td> [@expression2024]
<td><strong>FXN</strong></td> [@fox2019]
</tr> [@delatycki2019]
<tr> [@ncbi]
<td class="label">Full Name</td> [@omim]
<td>Frataxin</td> [@proteins]
</tr> [@httpswwwncbinlmnihgovgene]
<tr> [@httpsensemblorghomosapiensgenesummarygensg]
<td class="label">Chromosome</td> [@httpsomimorgentry]
<td>9q21.11</td> [@httpswwwuniprotorguniprotq]
</tr> [@fxn]
<tr> [@fxna]
<td class="label">NCBI Gene</td> [@httpswwwcurefaorg]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/2395" target="_blank">2395</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165060" target="_blank">ENSG00000165060</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/606829" target="_blank">606829</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q16595" target="_blank">Q16595</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Friedreich's Ataxia](/diseases/friedreichs-ataxia)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Dorsal root ganglia, Spinal cord, Cerebellum, Heart, Pancreas, Liver</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">GAA repeat expansion (intron 1, 90–1300 repeats)<br>p.I154F — missense<br>p.G130V — missense<br>p.W155R — missense<br>p.L106S — missense</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/friedreich's-ataxia" style="color:#ef9a9a">Friedreich's Ataxia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">53 edges</a></td>
</tr>
</table>

FXN — Frataxin

Introduction

Fxn — Frataxin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

FXN (Frataxin) is a nuclear gene located on chromosome 9q21.11 that encodes the mitochondrial protein frataxin, an essential component of the iron-sulfur (Fe-S) cluster biosynthesis machinery [@friedreichs1996].
Pathological expansion of a GAA trinucleotide repeat in intron 1 of FXN is the causative mutation in [Friedreich's Ataxia](/diseases/friedreichs-ataxia) (FRDA), the most common inherited ataxia, affecting approximately 1 in 50,000 individuals in
European populations [@friedreichs1996][@role2004].
The GAA expansion leads to epigenetic silencing of the FXN locus and dramatically reduced frataxin protein levels, resulting in mitochondrial iron accumulation, [oxidative stress](/mechanisms/oxidative-stress), and progressive neurodegeneration
predominantly affecting the dorsal root ganglia, [cerebellum](/brain-regions/cerebellum), and spinal cord [@frataxin2025].

The gene was identified in 1996 by Campuzano and colleagues, who discovered that Friedreich's Ataxia is caused by an intronic GAA triplet repeat expansion — the first example of a disease-causing intronic trinucleotide repeat [@friedreichs1996]. FXN is catalogued as NCBI Gene ID [^2395] and OMIM [^606829].

Gene Structure and Protein

Gene Organization

The FXN gene spans approximately 95 kb of genomic DNA and contains seven exons encoding a 210-amino acid precursor protein [@role2004].
Normal individuals carry 5–33 GAA repeats in intron 1, while affected individuals harbor 66–1,700 repeats on both alleles (homozygous expansion in ~96% of patients) or a GAA expansion on one allele and a point mutation
on the other (compound heterozygotes, ~4%) [@friedreichs1996][@phenotypic2024].

Frataxin Protein

The frataxin precursor is synthesized in the cytoplasm and imported into the mitochondrial matrix, where it undergoes two-step proteolytic processing by mitochondrial processing peptidase (MPP) to yield the mature 130-amino acid (14 kDa) protein [@role2004][@regulation2024]. The mature frataxin adopts a compact α-β sandwich fold consisting of:

N-terminal α-helix — contains acidic residues that form an iron-binding surface
Central β-sheet platform — five antiparallel β-strands forming the structural core
C-terminal α-helix — stabilizes the overall fold

The acidic ridge on the α-helix and β-sheet surface coordinates iron binding and mediates protein-protein interactions with the Fe-S cluster assembly complex [@regulation2024].

Normal Function

Iron-Sulfur Cluster Biosynthesis

Frataxin is an essential activator of the mitochondrial iron-sulfur (Fe-S) cluster assembly complex, which consists of the cysteine desulfurase NFS1, its partner protein ISD11, the scaffold protein ISCU2, and frataxin itself [@regulation2024]. Within this complex, frataxin:

Activates NFS1 cysteine desulfurase activity — stimulates sulfur transfer from free cysteine to ISCU2 for Fe-S cluster assembly [@regulation2024]
Facilitates iron delivery — acts as an iron chaperone, delivering Fe²⁺ to the ISCU2 scaffold for incorporation into nascent Fe-S clusters
Modulates allosteric regulation — controls the kinetics and specificity of Fe-S cluster assembly

Fe-S clusters are essential prosthetic groups for proteins involved in the mitochondrial [electron transport chain](/mechanisms/electron-transport-chain) (Complexes I, II, III), the citric acid cycle (aconitase), DNA repair, and numerous other cellular processes [@frataxin2025][@regulation2024].

Antioxidant Defense

Frataxin contributes to cellular antioxidant defenses through multiple mechanisms:

Proper Fe-S cluster assembly prevents iron accumulation and Fenton chemistry-driven [reactive oxygen species](/mechanisms/oxidative-stress) (ROS) generation
Frataxin regulates mitochondrial iron homeostasis, preventing toxic iron overload
Fe-S cluster-dependent enzymes are required for antioxidant pathways including glutathione metabolism and [NRF2](/proteins/nrf2)-dependent responses [@frataxin2025]

Brain Expression

Frataxin is expressed ubiquitously but is particularly abundant in tissues with high metabolic demands:

Dorsal root ganglia — large proprioceptive sensory [neurons](/entities/neurons) (primary site of degeneration in FRDA)
Spinal cord — posterior columns and spinocerebellar tracts
[cerebellum](/brain-regions/cerebellum) — dentate nucleus [neurons](/entities/neurons)
Heart — cardiomyocytes (explains cardiomyopathy in FRDA)
Pancreas — beta cells (explains diabetes in FRDA)
Liver — hepatocytes

Expression data is available from the [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=FXN).

Disease Associations

Friedreich's Ataxia

[Friedreich's Ataxia](/diseases/friedreichs-ataxia) (FRDA) is an autosomal recessive neurodegenerative and cardiac disease caused by insufficient frataxin protein [@friedreichs1996].
The GAA repeat expansion in intron 1 induces heterochromatin formation through H3K9 trimethylation and [DNA methylation](/entities/dna-methylation), silencing FXN transcription and reducing frataxin levels to 5–30% of normal [@role2004][@expression2024].

Clinical features develop typically in childhood or adolescence and include:

Progressive ataxia — loss of coordination affecting gait and limbs
Sensory neuropathy — loss of proprioception and vibration sense due to dorsal root ganglion degeneration
Dysarthria — progressive speech difficulties
Hypertrophic cardiomyopathy — present in ~60% of patients; the most common cause of death
Diabetes mellitus — develops in ~30% of patients
Scoliosis — progressive spinal curvature
Pes cavus — foot deformities

Longer GAA repeat expansions correlate with earlier onset, greater disease severity, and faster progression [@friedreichs1996][@phenotypic2024].
The inverse correlation between GAA repeat length and frataxin protein levels provides the mechanistic link between genotype and phenotype.

Compound Heterozygotes

Approximately 4% of FRDA patients are compound heterozygotes, carrying a GAA expansion on one allele and a conventional point mutation or deletion on the other [@phenotypic2024].
A 2024 study of phenotypic variation in compound heterozygotes found that non-GAA repeat mutations were associated with reduced cardiac disease, and patients with partial-function mutations showed relative sparing of
bulbar and upper limb function [@phenotypic2024].

Key Mutations

GAA trinucleotide repeat expansion (intron 1) — 90–1,300 repeats (normal: 5–33); most common mutation
p.I154F — missense affecting protein stability; common in compound heterozygotes
p.G130V — missense destabilizing the protein; atypical mild phenotype with retained frataxin function
p.W155R — disrupts iron-binding surface
p.L106S — reduces protein stability in the β-sheet core
p.D122Y — affects Fe-S cluster assembly interface

Pathological Mechanisms

Mitochondrial Iron Accumulation

Reduced frataxin levels impair Fe-S cluster biosynthesis, leading to mitochondrial iron overload. Excess mitochondrial iron generates hydroxyl radicals via Fenton reactions, causing oxidative damage to mitochondrial DNA, lipids, and proteins [@frataxin2025]. This creates a vicious cycle: oxidative damage further impairs mitochondrial function, which exacerbates iron dysregulation.

Electron Transport Chain Dysfunction

Fe-S clusters are essential cofactors for Complexes I, II, and III of the mitochondrial electron transport chain. Frataxin deficiency causes progressive loss of respiratory chain activity, reduced ATP production, and increased electron leakage generating superoxide [@frataxin2025][@regulation2024].

Selective Neuronal Vulnerability

The selective vulnerability of dorsal root ganglia [neurons](/entities/neurons) and cerebellar dentate nucleus neurons reflects their exceptionally high metabolic demands, large cell body size, long axons requiring extensive mitochondrial transport, and high dependence on Fe-S cluster-containing enzymes for proprioceptive signaling [@frataxin2025].

Therapeutic Approaches

Frataxin Replacement

Gene therapy: AAV-mediated delivery of functional FXN to the CNS and heart is under active preclinical development. A 2024 study demonstrated successful expression and processing of mature human frataxin after AAV gene therapy in mice [@friedreichs1996]
Protein replacement: Engineered frataxin fusion proteins with cell-penetrating peptides

Upregulation of Endogenous FXN

Histone deacetylase ([HDAC](/entities/hdac-enzymes) inhibitors — target heterochromatin at the FXN locus to reactivate transcription
Antisense oligonucleotides — targeting the R-loop structure formed by GAA repeats
Small molecules — various compounds under investigation to increase frataxin transcription [@expression2024]

Downstream Targets

Omaveloxolone (Skyclarys™) — FDA-approved NRF2 activator that boosts antioxidant defenses; first approved treatment for FRDA (2023)
Idebenone — synthetic coenzyme Q10 analog targeting mitochondrial electron transport
Iron chelators — deferiprone reduces mitochondrial iron accumulation
Resveratrol — activates frataxin expression and mitochondrial biogenesis

Brain Atlas Resources

[Allen Brain Atlas](https://brain-map.org)
[Allen Human Brain Atlas: FXN search](https://human.brain-map.org/microarray/search/show?search_term=FXN)
[Allen Mouse Brain Atlas: FXN search](https://mouse.brain-map.org/search/index.html?query=FXN)
[Allen Cell Type Atlas](https://portal.brain-map.org/atlases-and-data/rnaseq)
[BrainSpan Developmental Transcriptome](https://www.brainspan.org)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[Allen Brain Atlas](https://www.brain-map.org/)

Background

The study of Fxn — Frataxin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Unknown, Friedreich's Ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion (1996)](https://doi.org/10.1126/science.271.5254.1423)

[Unknown, The role of frataxin in Friedreich's Ataxia (2004)](https://doi.org/10.1007/s00018-004-3433-8)

[Unknown, Frataxin deficiency and the pathology of Friedreich's Ataxia across tissues (2025)](https://doi.org/10.1080/21688370.2025.2462357)

[Unknown, Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohort (2024)](https://doi.org/10.1002/acn3.52019)

[Unknown, The regulation of the disease-causing gene FXN (2024)](https://doi.org/10.3390/cells13121040)

[Unknown, Expression and processing of mature human frataxin after gene therapy in mice (2024)](https://doi.org/10.1038/s41598-024-59060-0)

[Fox NG, et al., Structure of the human frataxin-bound iron-sulfur cluster assembly complex provides insight into its activation mechanism. Nat Commun, 2019. . DOI (2019)](https://doi.org/10.1038/s41467-019-09989-y)

[Unknown, Delatycki MB, Bidichandani SI. Friedreich ataxia — pathogenesis and implications for therapies. Neurobiol Dis, 2019. . DOI (2019)](https://doi.org/10.1016/j.nbd.2019.104606)

Unknown, NCBI Gene: FXN (n.d.)

Unknown, OMIM: [606829](/genes) (n.d.)

Unknown, - [Proteins Index](/proteins)## External Links (n.d.)

- NCBI Gene:, https://www.ncbi.nlm.nih.gov/gene/2395 (n.d.)

- Ensembl:, https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165060 (n.d.)

- OMIM:, https://omim.org/entry/606829 (n.d.)

- UniProt:, https://www.uniprot.org/uniprot/Q16595 (n.d.)

- Allen Human Brain Atlas:, FXN expression (n.d.)

- ClinVar:, FXN variants (n.d.)

- Friedreich's Ataxia Research Alliance:, https://www.curefa.org (n.d.)

Pathway Diagram

The following diagram shows the key molecular relationships involving fxn discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving FXN — Frataxin discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

FXN — Frataxin

FXN — Frataxin

FXN — Frataxin

FXN — Frataxin

Introduction

Overview

Gene Structure and Protein

Gene Organization

Frataxin Protein

Normal Function

Iron-Sulfur Cluster Biosynthesis

Antioxidant Defense

Brain Expression

Disease Associations

Friedreich's Ataxia

Compound Heterozygotes

Key Mutations

Pathological Mechanisms

Mitochondrial Iron Accumulation

Electron Transport Chain Dysfunction

Selective Neuronal Vulnerability

Therapeutic Approaches

Frataxin Replacement

Upregulation of Endogenous FXN

Downstream Targets

Brain Atlas Resources

See Also

External Links

Background

References

Pathway Diagram

Pathway Diagram